|
|
|
|
Eur Respir J 2009,Jan,01;33(1):21-32; (PMID: 18768573)
The safety of long-acting beta(2)-agonist (LABA) treatment in asthma has been questioned following reported increased respiratory deaths when salmeterol was added to usual pharmacotherapy[...]
|
|
|
Cochrane Database Syst Rev 2009,Jan,01;(3):CD006480; (PMID: 19588394)
[...]BACKGROUND: Allergen exposure is one of the environmental factors seemingly associated with the development of asthma. If asthma is a multi-factorial disease, it is hypothesised that prevention might only prove effective if most or all relevant environmental factors are simultaneously avoided.[...]
|
|
|
Cochrane Database Syst Rev 2009,Jan,01;(3):CD006922; (PMID: 19588410)
BACKGROUND: Epidemiological evidence has suggested a link between beta(2)-agonists and increased asthma mortality. There has been much debate about possible causal links for this association, and whether regular (daily) long-acting beta(2)-agonists are safe.[...]
|
|
|
Cochrane Database Syst Rev 2009,Jan,01;(3):CD007949; (PMID: 19588447)
[...]BACKGROUND: Long-acting ss(2)- agonists (LABA) in combination with inhaled corticosteroids (ICS) are increasingly prescribed in asthmatic children. OBJECTIVES: To compare the safety and benefit of adding LABA to ICS with the same or an increased dose of ICS in [...] to ICS with the same or an increased dose of ICS in children with persistent asthma. SEARCH STRATEGY: We searched the Cochrane Airways Group Asthma Trials Register (May 2008). SELECTION CRITERIA: We included randomised controlled trials testing the combination of [...]
|
|
|
BMC Public Health 2009,Jan,01;9:88; (PMID: 19320986) [FULL TEXT AVAILABLE]
[...] except esophageal (female), pancreatic and prostate cancer, all cardiovascular diseases (except congestive heart failure), asthma, gallbladder disease, osteoarthritis and chronic back pain. We noted the strongest association between [...]
|
|
|
BMJ 2009,Jan,01;339:b2433; (PMID: 19589816) [FULL TEXT AVAILABLE]
[...] or allergic disorders. DATA EXTRACTION: Atopic eczema or dermatitis, food allergy, asthma, allergic rhinitis, and anaphylaxis, along with relevant immunological variables relating to the risk of allergic [...] reported a significant association: pooled odds ratio from case-control studies 2.84 (2.08 to 3.88). An overall odds ratio for the association between filaggrin gene mutations and asthma in people with atopic eczema was 2.79 (1.77 to 4.41) in case-control studies and 2.30 (1.66 to 3.18) in family studies.[...]
|
|
|
Cochrane Database Syst Rev 2009,Jan,01;(4):CD007695; (PMID: 19821436)
[...]BACKGROUND: An increase in serious adverse events with both regular formoterol and regular salmeterol in chronic asthma has been demonstrated in previous Cochrane reviews. OBJECTIVES: We set out to compare the risks of mortality and non-fatal serious adverse events in trials which have randomised [...]SELECTION CRITERIA: Controlled parallel design clinical trials on patients of any age and severity of asthma were included if they randomised patients to treatment with regular formoterol versus regular salmeterol (without randomised [...]
|
|
|
Cochrane Database Syst Rev 2009,Jan,01;(4):CD005538; (PMID: 19821348)
[...] as in adults, but these are rare. More research on optimum dosing and safety in asthmatic children is required.
|
|
|
Cochrane Database Syst Rev 2009,Jan,01;(4):CD006340; (PMID: 19821360)
BACKGROUND: The measurement of severity and control of asthma in both children and adults can be based on subjective or objective measures. It has been advocated that fractional exhaled [...]
|
|
|
Cochrane Database Syst Rev 2009,Jan,01;(4):CD005307; (PMID: 19821344)
[...]BACKGROUND: Consensus statements recommend the addition of long-acting inhaled ss2-agonists (LABA) only in asthmatic patients who are inadequately controlled on inhaled corticosteroids (ICS). It is not uncommon for some [...]) with inhaled corticosteroids alone (ICS alone) in steroid-naive children and adults with persistent asthma. We assessed two protocols: (1) LABA + ICS versus a similar dose of ICS (comparison 1) and (2) [...]
|
 3 4 5 6 7 8 9 10 
|
|
